Nizam's Institute of Medical Sciences, Department of Pharmacology and Therapeutics, Telangana, India.
Nizam's Institute of Medical Sciences, Department of Pharmacology and Therapeutics, Telangana, India.
Phytomedicine. 2022 Oct;105:154334. doi: 10.1016/j.phymed.2022.154334. Epub 2022 Jul 19.
Accelerated bone loss associated with aging and estrogen withdrawal is mediated in part by increased oxidative stress and inflammation.
Investigate dietary supplementation with a standardized aqueous extract of shilajit with clinically demonstrated antioxidant, anti-inflammatory, and collagen-promoting activity on attenuating bone loss in postmenopausal women with osteopenia.
Sixty postmenopausal women aged 45 - 65 years with osteopenia were randomized to receive 1 of 3 treatments daily for 48 weeks: (1) placebo, (2) 250 mg shilajit extract, or (3) 500 mg shilajit extract. Bone mineral density (BMD) of the lumbar spine (LS) and femoral neck (FN) were measured at weeks 0, 24, and 48, and circulating markers of bone turnover (CTX-1, BALP, RANKL, OPG), oxidative stress (MDA, GSH), and inflammation (hsCRP) at weeks 0, 12, 24, and 48.
BMD of both the LS and FN progressively decreased in women receiving placebo but was dose-dependently attenuated with shilajit extract supplementation, resulting in significantly increased percentage changes from baseline in BMD at 24- and 48-weeks in both supplemented groups compared to placebo (p < 0.001). CTX-1, BALP, and RANKL decreased, whereas OPG increased, in both groups supplemented with the shilajit extract, but not in the placebo group, resulting in significantly decreased or increased percentage changes from baseline, respectively. MDA was significantly decreased (p < 0.001) and GSH was significantly increased (p < 0.001) in both supplemented groups compared to placebo from week 12 for the duration of the study. Progressive reductions in hsCRP were observed in both supplemented groups, resulting in significantly decreased percentage changes from baseline in supplemented women compared to placebo (p < 0.001).
Daily supplementation with this shilajit extract supports BMD in postmenopausal women with osteopenia in part by attenuating the increased bone turnover, inflammation and oxidative stress that coincides with estrogen deficiency in this population at increased risk for osteoporosis and bone fractures.
与衰老和雌激素缺乏相关的加速骨丢失部分是由氧化应激和炎症增加介导的。
研究具有临床抗氧化、抗炎和促进胶原蛋白作用的标准化水提希拉杰特膳食补充剂对绝经后骨质疏松症妇女骨丢失的影响。
60 名年龄在 45-65 岁之间的绝经后骨质疏松症妇女被随机分为 3 组，每天接受 1 种治疗，共 48 周：（1）安慰剂，（2）250mg 希拉杰特提取物，或（3）500mg 希拉杰特提取物。在 0、24 和 48 周时测量腰椎（LS）和股骨颈（FN）的骨矿物质密度（BMD），在 0、12、24 和 48 周时测量循环骨转换标志物（CTX-1、BALP、RANKL、OPG）、氧化应激（MDA、GSH）和炎症（hsCRP）标志物。
接受安慰剂的妇女的 LS 和 FN 的 BMD 逐渐下降，但希拉杰特提取物补充剂呈剂量依赖性减弱，导致与安慰剂组相比，补充组在 24 和 48 周时的 BMD 百分比变化显著增加（p<0.001）。CTX-1、BALP 和 RANKL 在补充希拉杰特提取物的两组中降低，而 OPG 增加，但在安慰剂组中没有，导致分别从基线的百分比变化显著降低或增加。从第 12 周开始，与安慰剂相比，两组的 MDA 均显著降低（p<0.001），GSH 显著升高（p<0.001），持续整个研究期间。在补充组中观察到 hsCRP 的逐渐降低，与安慰剂组相比，补充组的 hsCRP 百分比变化显著降低（p<0.001）。
每日补充这种希拉杰特提取物可支持绝经后骨质疏松症妇女的 BMD，部分原因是通过减弱与该人群中雌激素缺乏相关的增加的骨转换、炎症和氧化应激，从而降低了骨质疏松症和骨折风险增加的风险。
